Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Maxim Group Downgrades Synaptogenix to Hold

Maxim Group analyst Jason McCarthy downgrades Synaptogenix (NASDAQ:SNPX) from Buy to Hold.
byBenzinga Newsdesk
December 19, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Maxim Group analyst Jason McCarthy downgrades Synaptogenix (NASDAQ:SNPX) from Buy to Hold.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca Announced Camizestrant Significantly Improved Progression-free Survival vs. Faslodex in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer

By Charles Gross
October 26, 4:47 AM
Positive high-level results from the SERENA-2 Phase II trial showed that AstraZeneca's next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant met the primary endpoint of demonstrating a statistically significant and clinically meaningful progression-free survival (PFS) benefit at both 75mg and 150mg dose levels versus Faslodex (fulvestrant) 500mg in post-menopausal patient

AZN